(Finance) – Abbott Laboratoriesan American pharmaceutical giant, has registered sales of the fourth quarter 2023 up 1.5% to $10.2 billion, or 2.1% on an organic basis and 11.0% on an organic basis and excluding sales related to COVID-19 testing. EPS was $0.91 (vs. $0.59 a year ago) andAdjusted EPS of 1.19 dollars (vs. 1.03 dollars).
Abbott expectsentire year 2024 an EPS between $3.20 and $3.40 and a Adjusted EPS between $4.50 and $4.70. The midpoint is below analysts’ estimates of $4.64 per share, according to LSEG data. Furthermore, it expects the organic growth of salesexcluding sales related to COVID-19 testing, will be between 8.0% and 10.0%.
“The strength and diversity of Abbott’s portfolio has driven our success in 2023,” he said CEO Robert B. Ford – We enter 2024 with one positive momentum and, with our highly productive pipeline, we are well positioned for growth in 2024 and beyond.”